Showing 4511-4520 of 5910 results for "".
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- Haag-Streit Introduces the Imaging Module 910 Slit Lamphttps://modernod.com/news/haag-streit-launhces-the-imaging-module-910-slit-lamp/2480718/Haag-Streit announced the launch of the Imaging Module 910 slit lamp. The device is instantly ready by the turn of a knob and does not require using software. Haag-Streit says capturing images is equally easy—pressing the camera trigger button is all that it takes. "
- Show Organizers Announce that Vision Expo+, a Complimentary, Virtual Extension of the Vision Expo Experience Will be Offered April 1–8, 2022https://modernod.com/news/show-organizers-announce-that-vision-expo-a-complimentary-virtual-extension-of-the-vision-expo-experience-will-be-offered-april-1-8-2022/2480715/The Vision Council and RX, co-organizers of Vision Expo, announced that Vision Expo+, a complimentary digital extension of the Vision Expo experience, will be offered from Friday April 1 to Friday, April 8, 2022. Vision Expo+ will be delivered through
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-us-lightsite-iii-clinical-trial-meets-primary-efficacy-endpoint-in-improving-vision-in-dry-amd-patients/2480712/LumiThera announced positive findings in its LIGHTSITE III multicenter clinical trial in non-neovascular (dry) age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked, randomized, multicenter clinica
- Visus Therapeutics Initiates Phase 3 Pivotal Trials of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-3-pivotal-trials-of-brimochol-pf-for-the-treatment-of-presbyopia/2480710/Visus Therapeutics announced the launch of the first of two pivotal phase 3 trials (BRIO-I and BRIO-II) for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. The initiation of the BRIO trials follows compelling topline data from th
- Innovega Announces Public Funding Campaign with StartEngine.comhttps://modernod.com/news/innovega-announces-public-funding-campaign-with-startenginecom/2480709/Innovega, a developer of next-generation display eyewear for augmented reality, virtual reality (AR/VR) and Metaverse applications, launched an online funding campaign with StartEngine, a equity crowdfunding platform. Innovega has raised more than $16 million in total funding,
- Horizon Therapeutics and IAPB Partner to Advocate for Better Eye Healthhttps://modernod.com/news/horizon-therapeutics-and-iapb-partner-to-advocate-for-better-eye-health/2480708/The International Agency for the Prevention of Blindness (IAPB) has announced that Horizon Therapeutics has joined IAPB as a Global Patron. Working together, Horizon and IAPB will advocate to bring better eye health to all at global, country and regional levels. Horizon and IAPB w
- EssilorLuxottica and CooperCompanies Finalize Joint Venturehttps://modernod.com/news/essilorluxottica-and-coopercompanies-finalize-joint-venture/2480705/EssilorLuxottica and CooperCompanies have announced the finalization of their joint venture agreement for SightGlass Vision. This collaboration accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion
- Bryan Wolynski Named Chief Technology Officer at Lighthouse Guildhttps://modernod.com/news/bryan-wolynski-named-chief-technology-officer-at-lighthouse-guild/2480702/Bryan Wolynski, OD, FAAO, has been named Chief Technology Officer at Lighthouse Guild. Dr. Wolynski will oversee all technology resources for the organization, including the recently opened Lighthouse Guild Technology Center, and will develop strategies to bring the latest technological advances
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo